로그인
토토사이트
먹튀사이트/제보
업체홍보/구인
신규사이트
지식/노하우
놀이터홍보
판매의뢰
스포츠분석
뉴스
후기내역공유
커뮤니티
포토
포인트
보증업체
카지노 먹튀
토토 먹튀
먹튀제보
구인
구직
총판
제작업체홍보
카지노
토토
홀덤
카지노 노하우
토토 노하우
홀덤 노하우
기타 지식/노하우
유용한 사이트
토토 홍보
카지노 홍보
홀덤 홍보
꽁머니홍보
신규가입머니
제작판매
제작의뢰
게임
축구
야구
농구
배구
하키
미식축구
스포츠뉴스
연예뉴스
IT뉴스
카지노 후기
토토 후기
홀덤 후기
자유게시판
유머★이슈
동영상
연예인
섹시bj
안구정화
출석하기
포인트 랭킹
포인트 마켓
로그인
자동로그인
회원가입
정보찾기
뉴스
더보기
[]
푸틴 "얄타회담처럼 우크라전도 현실 인정해야"…점령지 인정 요구(종합)
N
[]
[미중러 정상회담] 中, 트럼프에 젠슨황 질문한 美기자 취재 차단
N
[]
한덕수 파기환송에 與 '조희대 탄핵' 카드…野 반발 속 정국 격랑
N
[]
트럼프 손짓에도 선전 북미회담 불발…대화 재개 문턱 여전
N
[]
[수능] "공부 열심히 해도 'AI 딸깍'하면"…시험 끝나고도 분통(종합)
N
커뮤니티
더보기
[유머★이슈]
바란 은퇴보다 더 소름돋는점
[유머★이슈]
오늘 국군의날 예행연습에 최초 공개된 장비들
[유머★이슈]
손흥민이 한국 병역 시스템에 영향 끼친 것.
[유머★이슈]
시댁의 속터지는 스무고개식 대화법
[유머★이슈]
엄마. 나 여자 임신시켜버렸어
목록
글쓰기
[IT뉴스]Orum Plunges on Clinical Halt; ENCell, VUNO Jump[K-Bio Pulse]
온카뱅크관리자
조회:
78
2026-09-22 07:07:25
<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="7FnTx1yOEA"> <div contents-hash="c03f962a2ba1453afec57f2416aa559bb92c477c88fbe99a8b535db2a49a5052" dmcf-pid="z3LyMtWIIj" dmcf-ptype="general"> <div> This article was released as <strong>Pharm Edaily Premium Content</strong> on September 21, 2026, at 7:00 AM. </div> </div> <p contents-hash="1378519b42ea8ca1c84bfbf5c8fa7f3dc0e2169a218a4024fca9a92acb8687d4" dmcf-pid="q0oWRFYCDN" dmcf-ptype="general">[Kim Saemi, Edaily Repoeter] South Korean biotech stocks diverged sharply on Sept. 18 as Orum Therapeutics, Inc. plunged to the daily lower limit following another clinical setback, while ENCell Co.,Ltd. and VUNO Inc. posted double-digit gains on patent and research news.</p> <figure class="figure_frm origin_fig" contents-hash="84459033322b82cf6ee2a63bfb04ae1f84004825ccc5595af2191aa326fa3e10" dmcf-pid="BpgYe3Ghra" dmcf-ptype="figure"> <p class="link_figure"><img alt="Lee Seung-joo, CEO of Orum Therapeutics (Photo by Lee Young-hoon, Edaily)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202609/22/Edaily/20260922070454956oqkj.jpg" data-org-width="1280" dmcf-mid="ukVkzCEoOc" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202609/22/Edaily/20260922070454956oqkj.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> Lee Seung-joo, CEO of Orum Therapeutics (Photo by Lee Young-hoon, Edaily) </figcaption> </figure> <p contents-hash="962f8054b6e5d4f42e40fb5916758bb95aef4acfb866a884ae856f465b194aa2" dmcf-pid="bUaGd0Hlsg" dmcf-ptype="general"><strong>BMS Drops ORM-6151, Orum's DAC PoC Back to Square One</strong></p> <p contents-hash="f42f636ffd3f9f32ffaae669a66d9250fc6e6f333e92b7bb9025a6e486b2e973" dmcf-pid="KuNHJpXSso" dmcf-ptype="general">According to KG Zeroin's MP DOCTOR, Orum closed at 37,400 won, down 29.96%, after Bristol Myers Squibb, or BMS, discontinued clinical development of ORM-6151, an acute myeloid leukemia candidate acquired from Orum. The stock had also hit the lower limit in the previous day's after-hours market.</p> <p contents-hash="af3d1d3e2167b454820451e395aef01f88986dfbbe36105c5c0876853e4ecbdd" dmcf-pid="97jXiUZvEL" dmcf-ptype="general">The reaction reflected more than the loss of a single asset. The setback marked the second clinical-stage setback involving Orum's core degrader-antibody conjugate, or DAC, technology, raising uncertainty over the platform's clinical proof of concept, or PoC.</p> <p contents-hash="219378b92bd53532bcd2948a14daf801b55ce3aeb276e96d7f37959a62b67393" dmcf-pid="2zAZnu5Trn" dmcf-ptype="general">Orum discontinued a Phase 1 trial of ORM-5029 last year following a serious adverse event, while BMS has now halted Phase 1 development of ORM-6151 after reviewing patient data. The two candidates target HER2 and CD33, respectively, but both use Orum's DAC technology to deliver a GSPT1 degrader.</p> <p contents-hash="d3c2ad74d67f68f08819ab1340b6f202f47d164272bc14c0d2f238241343dfaa" dmcf-pid="VT8wbSrNEi" dmcf-ptype="general">ORM-6151 had been expected to provide external clinical validation of the platform. BMS acquired the program in 2023 for up to $180 million, including $100 million upfront, and conducted Phase 1 trials in the United States, Europe and Canada.</p> <p contents-hash="6fea6a7902585e8341a26c37fed1af69effb53c02b08887a09ae4efeb6a4b99c" dmcf-pid="fy6rKvmjrJ" dmcf-ptype="general">Orum's next key candidate, ORM-1153, received U.S. Food and Drug Administration clearance for a Phase 1 trial last month but has yet to begin patient dosing. Other internal programs remain in research or preclinical stages.</p> <p contents-hash="428b3fd806be4e0757f91f00ed864cf16cb5a981a43496d3adba6ea40540f7af" dmcf-pid="4WPm9TsAmd" dmcf-ptype="general">The financial impact may be secondary. Orum will lose up to $80 million in potential milestones, but does not have to return the $100 million upfront payment.</p> <p contents-hash="fef17542e21c4a3c250a2e3cf88c935e2486657796ebdeba203068793af06c0c" dmcf-pid="8YQs2yOcme" dmcf-ptype="general">"This isn't simply about losing one pipeline asset. Orum now has to demonstrate PoC for its DAC platform all over again," a biotech industry official said. "That puts the company's valuation under pressure."</p> <p contents-hash="f5376477472a143581265c1eeafff5b57fd24dbf691f483b13e9b67081d9bda4" dmcf-pid="6GxOVWIkOR" dmcf-ptype="general"><strong>ENCell Surges 26% as Patent News Sparks Trading Frenzy</strong></p> <p contents-hash="a6ec7bbf15ed15859a47591033bb87fafb3b276194b689ba2e4723ddf0ac8c5c" dmcf-pid="PHMIfYCEDM" dmcf-ptype="general">ENCell surged to the daily upper limit of 6,820 won intraday before closing at 6,620 won, up 26.1%. Trading volume jumped to 2.77 million shares, about 182 times the previous day's level.</p> <p contents-hash="77647937cb40e71600f1d9b669c4baaa8a093df894ccd36c0184646e2f71f3d7" dmcf-pid="QXRC4GhDwx" dmcf-ptype="general">The rally appeared to follow news that ENCell and the Samsung Life Public Welfare Foundation had secured a U.S. patent for mesenchymal stem cell culture technology. The technology, already used to manufacture EN001, ENCell's investigational treatment for Charcot-Marie-Tooth disease type 1A, or CMT1A, is designed to suppress cellular aging while preserving stem cell differentiation and proliferation.</p> <p contents-hash="26e9add6b4856c474a5ceadd1561cac9193a213c8e6f0a21d75dfbb816bc6b95" dmcf-pid="xZeh8HlwrQ" dmcf-ptype="general">"This patent covers a core manufacturing technology for the stable production of high-quality source cells for EN001," an ENCell official said, adding that it would strengthen global IP protection for the candidate.</p> <p contents-hash="7066bf57f015f261de572cc73064da9c75137e8bc4aaaf701e765b4f290641f0" dmcf-pid="yiG4ld8BsP" dmcf-ptype="general">Still, the announcement did not involve newly developed technology or fresh clinical data. Rather, it secured U.S. intellectual property protection for technology already used in EN001's manufacturing process, raising questions over whether the news alone justified a 26% jump in market value.</p> <p contents-hash="d6e6ae37d6099e69e0b1a210572d9f695ed7593582d7a889165573b7ba0c60bb" dmcf-pid="WnH8SJ6bE6" dmcf-ptype="general"><strong>VUNO Jumps 16% on Month-Old Research</strong></p> <p contents-hash="5e43d395cdb086aa82122fb65f47a268187239154cfd547ba486a8f04a608b4d" dmcf-pid="Yv4DBlwar8" dmcf-ptype="general">Medical AI company VUNO surged 16.3% to close at 5,030 won after announcing an AI model designed to predict atrial fibrillation risk using real-world data from its HATIV P30 portable electrocardiogram device.</p> <p contents-hash="49b79d8a541073bf3e06c07c19a520b4cda638b648fcf7efd27aba623d196487" dmcf-pid="GT8wbSrND4" dmcf-ptype="general">The study analyzed 386,519 ECG recordings from 8,206 users. Unlike conventional ECG AI focused on detecting existing arrhythmias, VUNO's model predicts atrial fibrillation risk within seven, 14 and 31 days from a normal ECG. It achieved an AUROC of 0.787 for 31-day prediction, suggesting potential to expand ECG AI from detection to prediction.</p> <p contents-hash="fcc6d2200aa7cb2d11f5d759af989b104c41cebc55482ab55cd287bd120fbf17" dmcf-pid="Hy6rKvmjIf" dmcf-ptype="general">However, the findings were not new. They were already published Aug. 20 in JMIR Medical Informatics. A separate analysis involved just 144 high-risk patients, with five newly detected cases of atrial fibrillation. The technology has also yet to generate new regulatory approvals or revenue.</p> <p contents-hash="77b13b05beab9aae57e4e2f049705bd5d75323b164361a8dcc69be7e05312d94" dmcf-pid="XWPm9TsAwV" dmcf-ptype="general">"VUNO's shares had fallen sharply following its rights offering decision, so this news may have served as a short-term rebound catalyst," a medical device industry official said.</p> <p contents-hash="9b466795b9b6a6bbc83332332f248a2f92b7440f5296ad5fe4af13ac85ed6f6e" dmcf-pid="ZYQs2yOcs2" dmcf-ptype="general">VUNO announced Sept. 4 that it would raise 31.4 billion won through a rights offering to existing shareholders, followed by a public offering of any unsubscribed shares.</p> <p contents-hash="c7c740efec91e68919255286b258af3644c14ebfb02b3de304316023c7b3be62" dmcf-pid="5GxOVWIkE9" dmcf-ptype="general">김새미 (bird@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>
댓글등록
댓글 총
0
개
맨위로
이번주
포인트
랭킹
매주 일요일 밤 0시에 랭킹을 초기화합니다.
1
4,000
상품권
2
3,000
상품권
3
2,000
상품권
업체홍보/구인
더보기
[구인]
유투브 BJ 구인중이자나!완전 럭키비키자나!
[구인]
에카벳에서 최대 조건으로 부본사 및 회원님들 모집합니다
[구인]
카지노 1번 총판 코드 내립니다.
[구인]
어느날 부본사 총판 파트너 모집합니다.
[구인]
고액전용 카지노 / 헬렌카지노 파트너 개인 팀 단위 모집중 최고우대
놀이터홍보
더보기
[홀덤 홍보]
텍사스홀덤 핸드 순위- 홀카드의 가치
[홀덤 홍보]
텍사스홀덤 핸드 순위 - 프리플랍(Pre-Flop) 핸드 랭킹
[토토 홍보]
미니게임개발제작 전문업체 포유소프트를 추천드립니다.
[토토 홍보]
2023년 일본 만화 판매량 순위 공개
[토토 홍보]
무료만화 사이트 보는곳 3가지 추천
지식/노하우
더보기
[카지노 노하우]
혜택 트렌드 변화 위험성 다시 가늠해 보기
[카지노 노하우]
호기심이 부른 화 종목 선택의 중요성
[카지노 노하우]
카지노 블랙잭 카드 조합으로 히트와 스탠드를 결정하는 방법
[카지노 노하우]
흥부가 놀부될때까지 7
[카지노 노하우]
5월 마틴하면서 느낀점
판매의뢰
더보기
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
포토
더보기
채팅하기